Highlights

  • Cogstate (ASX:CGS) reported record US$89 million in new clinical-trial contracts during FY26.
  • The company entered FY27 with US$118.5 million of contracted future revenue.
  • FY26 Revenue increased 15% to US$60.9 million, supported by clinical-trial activity.
  • The company continues investing in AI-enabled clinical-trial workflows through FY28.

Cogstate (ASX:CGS) continues to build its position in computerised cognitive testing for clinical trials, with its FY26 results highlighting contract growth, revenue expansion and Investment in future capabilities. The company’s shares were trading at AUD 3.08, up 1.32% at the time of writing on 21 August 2026.

The company reported its FY26 full-year results for the year ended 30 June 2026 on 18 August 2026, with the update highlighting record contract wins and an expanded future revenue pipeline. The results provided further visibility into Cogstate’s contracted workload while also showing the impact of ongoing investment initiatives.

For investors assessing Cogstate (ASX:CGS), the focus remains on the company’s ability to convert its growing contract base into revenue while maintaining margins and managing investment requirements.

What is happening with Cogstate?

Cogstate provides computerised cognitive testing solutions used in clinical trials, particularly in central nervous system and Alzheimer’s disease research, along with a smaller healthcare segment.

The company’s FY26 results highlighted record contract activity, with the Business securing a higher level of new clinical-trial commitments during the year. The expanded contract base provides visibility into potential future revenue generation, although the timing of revenue recognition depends on trial execution and project schedules.

Cogstate’s business model remains closely linked to pharmaceutical and biotechnology research activity, where Demand can vary depending on clinical-trial activity and broader industry conditions.

Latest company developments

The key development from Cogstate’s FY26 results was the record level of new contract wins. The company signed US$89 million of net new clinical-trial sales contracts during FY26, representing a 116% increase, and entered FY27 with US$118.5 million of contracted future revenue.

Of this contracted future revenue, approximately US$48.3 million is expected to be recognised during FY27.

The company is also investing in AI-enabled clinical-trial workflows, including automated rater Training and monitoring capabilities, as part of a two-year development programme extending through FY28.

Cogstate also declared a fully Franked Dividend of A$0.04 per share, reflecting its approach towards Shareholder returns while continuing investment in business development.

What do the numbers say?

Cogstate reported FY26 revenue of US$60.9 million, representing a 15% increase compared with the previous year. EBITDA increased 14.9% to US$18.3 million, while net profit after tax reached US$11.9 million, with Diluted Earnings per Share of approximately US$0.07.

The company maintained an EBITDA Margin of 30% and an EBIT margin of 25%. However, gross margin declined to 58% from 61%, reflecting changes in delivery costs and business mix.

The clinical-trials segment remained the primary contributor, generating US$58.4 million in revenue and US$33.3 million in contribution at a 57% margin. The healthcare segment contributed US$2.5 million in revenue with an 81% margin.

Cogstate reported US$34.8 million in cash and no debt, providing financial capacity to support ongoing investment initiatives. Management also indicated that FY27 earnings are expected to have a second-half weighting, with the June 2027 half expected to contribute more than the December 2026 half.

What could drive the shares from here?

The conversion of Cogstate’s contract pipeline into recognised revenue remains a key Factor for future performance. Continued execution across clinical-trial programmes could support revenue growth and provide further visibility over earnings.

The company’s exposure to Alzheimer’s disease and broader central nervous system research remains an important demand driver, as clinical-trial activity influences demand for cognitive assessment solutions.

Investment in AI-enabled workflows could also influence future operating efficiency and differentiation if the technology delivers expected benefits.

The company’s debt-free Balance Sheet and contracted revenue base provide additional visibility, while growth in the healthcare segment could provide another avenue for expansion.

Risks investors should watch

Cogstate remains exposed to changes in pharmaceutical and biotechnology research spending, particularly within Alzheimer’s and central nervous system clinical trials. Delays, cancellations or changes in trial activity could affect revenue timing.

Contract timing is another consideration, as large Clinical Trials may result in uneven revenue recognition across reporting periods.

The decline in gross margin requires monitoring, as sustained pressure on delivery costs could affect profitability. The AI development programme also carries execution risk, as investment returns may take time to materialise.

Currency movements remain relevant due to the company’s US dollar reporting and international operations. As a smaller specialised technology provider, Cogstate’s valuation may also be sensitive to changes in investor sentiment.

Investor takeaway

Cogstate (ASX:CGS) enters FY27 with an expanded contract pipeline and increased visibility following its FY26 results. The company reported record US$89 million in new clinical-trial contracts, US$118.5 million in contracted future revenue and revenue growth during the year.

The key focus ahead will be on converting contracted work into recognised revenue, maintaining margins and delivering outcomes from its AI investment programme. While the company has increased visibility through its contract base, investors will continue monitoring clinical-trial demand, execution and profitability trends.